



## EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

July 27, 2022

WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 3, 2022 to report its second quarter 2022 financial results and highlight recent corporate developments.

To access the live conference call, please register using the audio conference link: <https://register.vevent.com/>. A live audio webcast of the event can be accessed via the Investors section of the Company website at [www.eyepointpharma.com](http://www.eyepointpharma.com). A webcast replay will also be available on the corporate website at the conclusion of the call.

### About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

### Investors:

Christina Tartaglia  
Stern IR  
Direct: (212)-698-8700  
[christina.tartaglia@sternir.com](mailto:christina.tartaglia@sternir.com)

### Media Contact

Amy Phillips  
Green Room Communications  
Direct: 412-327-9499  
[aphillips@greenroompr.com](mailto:aphillips@greenroompr.com)



Source: EyePoint Pharmaceuticals, Inc.